T. Rowe Price reports 4.9% stake in Guardant

T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Guardant Health, Inc..

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Guardant Health, Inc.. The firm held 6,514,828 shares of Guardant Health common stock, representing 4.9% of the class as of June 30, 2026.

T. Rowe Price reported sole voting power over 6,359,951 shares and sole dispositive power over 6,514,828 shares, with no shared voting or dispositive power. The filer expressly denied that this filing should be construed as an admission of beneficial ownership of these securities.

Key Figures

Beneficially owned shares: 6,514,828 shares Percent of class: 4.9% Sole voting power: 6,359,951 shares +2 more

5 metrics

Beneficially owned shares 6,514,828 shares Common stock beneficially owned by T. Rowe Price Associates, Inc.

Percent of class 4.9% Percentage of Guardant Health common stock class held

Sole voting power 6,359,951 shares Shares for which T. Rowe Price can solely vote or direct the vote

Sole dispositive power 6,514,828 shares Shares for which T. Rowe Price can solely dispose or direct disposition

Shared voting power 0 shares No shared voting power reported

Key Terms

beneficial owner, Sole Voting Power, Sole Dispositive Power, Percent of class

4 terms

beneficial owner financial

"shall not be construed as an admission that Price Associates is the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Sole Voting Power financial

"Sole Voting Power 6,359,951.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"Sole Dispositive Power 6,514,828.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Percent of class financial

"Percent of class: 4.9 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Guardant Health (GH) shares does T. Rowe Price Associates, Inc. report owning?

T. Rowe Price Associates, Inc. reports beneficial ownership of 4.9% of Guardant Health’s common stock. This corresponds to 6,514,828 shares of GH common stock as disclosed in the Schedule 13G/A amendment.

How many Guardant Health (GH) shares does T. Rowe Price Associates, Inc. have voting power over?

T. Rowe Price Associates, Inc. reports sole voting power over 6,359,951 shares of Guardant Health common stock. It reports no shared voting power in this Schedule 13G/A filing.

How many Guardant Health (GH) shares can T. Rowe Price Associates, Inc. dispose of?

T. Rowe Price Associates, Inc. reports sole dispositive power over 6,514,828 shares of Guardant Health common stock and no shared dispositive power, meaning it alone can direct the disposition of those shares.

What total number of Guardant Health (GH) shares are beneficially owned by T. Rowe Price Associates, Inc.?

T. Rowe Price Associates, Inc. reports beneficial ownership of 6,514,828 GH common shares. This stake represents 4.9% of Guardant Health’s outstanding common stock as disclosed in the Schedule 13G/A amendment.

Does T. Rowe Price Associates, Inc. admit beneficial ownership of Guardant Health (GH) shares in this filing?

No. T. Rowe Price Associates, Inc. expressly denies that this filing should be construed as an admission that it is the beneficial owner of the Guardant Health securities referenced.

When is the ownership information for Guardant Health (GH) in this Schedule 13G/A effective?

The ownership information is stated as of June 30, 2026. As of that date, T. Rowe Price Associates, Inc. reported holding 6,514,828 shares, representing 4.9% of Guardant Health’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 10:38 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

GUARDANT HEALTH INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

40131M109

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 40131M109

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,359,951.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,514,828.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,514,828.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: GUARDANT HEALTH INC
(b)	Address of issuer's principal executive offices: 3100 HANOVER STREET, PALO ALTO, CA, 94304
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 40131M109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6514828
(b)	Percent of class: 4.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 6359951
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 6514828
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	08/14/2026